One that spent $26m on interest bill
has NET payables of another $28mall in just a quarter!!!.....before even doing a thing.....POOOoooOOOOFFF up in smoke
That's what doing FDA trials looks like. ACTUALLY doing multiple trials.
Talking about doing trials is what you have here.
Not doing = no demand for shares, regardless of price offered.
Given the recent last CR, MSB could do another CR for around the same and perhaps a touch more. Not ideal but I'm confident it could be done.
CYP has a 'hail Mary' that someone saves them.
This company is going to pay dearly for the MEND trial. Credibility is lost at a critical stage.
(20min delay)